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Abstract
Aim: To study the cellular distribution of CCN3(NOV) and to determine if the carboxyterminus
of CCN3 is hidden or masked due to high affinity interactions with other partners. CCN3 was
detected using affinity purified antibodies (anti-K19M-AF) as well as a Protein A purified anti-K19M
antibodies (anti-K19M IgG) against a C-terminal 19-aminoacid peptide (K19M) of human CCN3
protein. The antibodies were applied in indirect immunofluorescence tests and immunoenzyme
assays on glial tumor cell line, G59, and its CCN3-transfected variant G59/540 and the
adrenocortical cell line, NCI-H295R.
Results: Anti-K19M-AF antibodies reacted against K19M peptide in ELISA and recognized two
bands of 51 kDa and 30 kDa in H295R (adrenocortical carcinoma) cell culture supernatants by
immunoblotting. H295R culture supernatants which contained CCN3 as shown by immunoblotting
did not react with anti-CCN3 antibodies in liquid phase. Anti-CCN3 antibodies stained the surface
membranes of non-permeabilized H295R and cytoplasm in permeabilized H295R cells. Similarly,
anti-CCN3 stained surface membranes of G59/540, but did not react with G59 cells. Prominent
cytoplasmic staining was observed in G59/540, as well as the cell footprints of G59/540 and H295R
were strongly labeled.
Conclusions: The K19M-AF antibody directed against the C-terminal 19-aminoacid peptide of
CCN3 recognized the secreted protein under denaturing conditions. However, the C-terminal
motif of secreted CCN3 was not accessible to K19M-AF in liquid phase. These anti-CCN3
antibodies stained CCN3 protein which was localized to cytoplasmic stores, cell membranes and
extracellular matrix. This would suggest that cytoplasmic and cell membrane bound CCN3 has an
exposed C-terminus while secreted CCN3 has a sequestered C-terminus which could be due to
interaction with other proteins or itself (dimerization). Thus the K19M-AF antibodies revealed at
least two conformational states of the native CCN3 protein.
Introduction
The CCN3 protein belongs to an emerging family of
growth regulators referred under the CCN acronym
(cysteine-rich protein, Cyr61, connective tissue growth
factor, CTGF, and the nephroblastoma overexpressed
gene, nov; CCN 1–3 respectively) [1-3]. The CCN family
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now comprises six identified members with properties of
both positive and negative regulators of cell growth, shar-
ing a common multimodular organization. New mem-
bers of the CNN family have been described over the past
few years, and recent reviews on the CCN proteins high-
light their intimate involvement in a variety of key biolog-
ical processes including development, angiogenesis, and
cancer [1-4].
The CCN3 (NOV) gene had been initially characterized as
an integration site for the myeloblastosis associated virus
MAV [5] which induces kidney tumors resembling neph-
roblastoma and Wilms tumor [6]. In human and animal
tumors, the expression of the CCN3 gene was found to be
altered either positively or negatively [7-11]. Experiments
performed in our laboratory have established that CCN3
is a marker of tumor differentiation in Wilms tumors [12]
and several other tumor types [unpublished observa-
tions]. Furthermore, an increasing amount of results
assigns growth inhibitory functions to CCN3 in several
conditions ([7,8,13-15], Manara et al. submitted).
The CCN proteins share a strikingly conserved multimod-
ular organization with distinctive functional features [1].
From the amino to the carboxy terminus of these proteins,
four modules can be recognized : an insulin-like growth
factor (IGF) binding protein (IGFBP)-type motif, fol-
lowed by a Von Willebrand type C (VWC) domain likely
responsible for oligomerisation, a thrombospondin type
1 (TSP1) repeat, responsible for interaction with extracel-
lular matrix proteins, and a carboxy-terminal module
(CT), postulated to represent a dimerization domain, as it
contains a cysteine-knot motif that is present and
involved in the dimerization of several growth factors
such as nerve growth factor (NGF), transforming growth
factor -2 (TGF-2) and platelet derived growth factor BB
(PDGFB).
The multimodular structure of CCN3 and other CNN pro-
teins raises interesting questions as to participation of
each individual module in conferring the biological prop-
erties to the full length proteins. Either the biochemical
functions of the individual IGFBP, VWC, TSP and CT
modules are indeed conserved and in sum determine the
ultimate function of the full length protein, or each mod-
ule confers on the whole protein specific biological func-
tions which may vary from the conserved function, and
either substitute or add to those of individual modules.
Application of the yeast two-hybrid system and co-precip-
itation strategies to identify proteins interacting with
CCN3 has revealed that full length CCN3 interacts with
several receptors, signaling molecules, and proteins of the
extracellular matrix (16–19), suggesting functional
involvement of CCN3 in cell signaling and adhesion
regulation.
Our results also established that truncated isoforms of
CCN3 could bind specific targets and pointed the CT
domain of CCN3 as a critical determinant for protein
interaction. This led us to hypothesize that truncated iso-
forms of CCN3 could also modulate its biological activity
(3). The question therefore arises whether different con-
formational states exist due to multiple protein interac-
tions and thereby the presentation of known antigenic
epitopes.
In the present study we have used an immunological
approach to establish the cellular distribution of CCN3 in
cell lines representing adrenocortical and glioblastoma
tumors and to ask whether the CT module of CCN3 exists
in different conformational states depending on its
involvement in protein interactions and cellular location.
We now provide evidence that the CT end of CCN3 exists
in more than one conformational state.
Results
Cell culture supernatants and cellular lysates from the
H295R, G59/540, and parental G59 cell lines were elec-
trophoresed under denaturing conditions and immunob-
lotted with anti-K19M IgG antibody. Immunoblot
analysis revealed secreted forms of CCN3 for the H295R
and G59/540 cell lines, consisting of two distinct bands at
51 kDa and 30 kDa [Figure 1A]. The latter likely corre-
sponded to the previously described amino-truncated
CCN3 isoform [3]. Intracellular CCN3 proteins were also
detected in these cell lines. However, in addition to the
two bands at 48 kDa and 30 kDa, two other high molecu-
lar species reacting positively with the antibodies were
also detected in the lysates [Figure 1B]. The different sizes
of these various isoforms likely results from post-transla-
tional modifications and oligomerisation of CCN3
protein.
When tested in ELISA, pre-incubation of the anti-K19M-
AF antibodies with CCN3-containing H259R supernatant
did not affect the binding of anti-K19M-AF antibodies to
the K19M peptide coated on microtitre plates (Figure 2).
Under identical conditions, the absorption of K19M-AF
antibodies with serial dilutions of K19M peptide showed
a dose-dependent absorption pattern with 7.78 µg/ml
K19M peptide, yielding a 50% reduction in the binding of
anti-K19M-AF to K19M peptide coated on plates (Figure
3). These results suggested that the K19M-AF antibodies
did not recognize the CCN3 protein in its native configu-
ration, whereas it can be detected in the same sample after
denaturation and Western blotting.Cell Communication and Signaling 2004, 2:9 http://www.biosignaling.com/content/2/1/9
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When fixed and non-permebialized cells were used in cell-
ELISA with anti-K19M-AF antibodies it was shown that
positive reaction of the antibodies could be recorded with
H295R cells which are known to synthesize and secrete
CCN3 protein, while the reaction with G59 cells was in
the ranges of the negative background. After
permebialization of the cells the intensity of the reaction
was increased but a significantly positive reaction was
recorded with H295R cells (Figure 4).
Since CCN3 was secreted by H259R cells, it was important
to check whether it could bind cell surface. Evidence for
this would lend support to the previous suggestion of an
autocrine mechanism of control by the CCN3 protein. To
explore this possibility cells from H259R, G59/540 and
G59 cell lines were incubated for 1 h on ice in the presence
of supernatant containing CCN3 protein and then ana-
lyzed by cell ELISA as described above. The results
obtained showed that such a treatment did not increase
the intensity of the reaction with anti-K19M-AF bound to
the cell surface. These experiments demonstrated that
H295R, and G59/540 which expressed CCN3 on the cell
surface and no further absorption occurred, and the
control G59/540 cells did not absorb CCN3 from the cul-
ture supernatant (data not shown).
Cellular Localization of CCN3
Paraformaldehyde fixed, non-permeabilized H259R cells
treated with the anti-K19M antibody (Protein A purified)
exhibited immunofluorescent membrane specific staining
distributed over the cell surface (Figure. 5A) while simi-
larly treated G59 CCN3 negative cells did not stain (not
shown). The CCN3-transfected glioblastoma cell line
G59/540 stained positively with a similar localization of
the reaction product (Figure 5B – G540). Interestingly,
since cells grown on coverslips and fixed in
paraformadehyde tend to slough, we did note the pres-
ence of positively staining cell footprints, suggesting dep-
osition of CCN3 protein in a secretable extracellular
matrix (Figures 5C,5D). After ethanol/formalin fixation
and further permeabilization of the cells with 0.1% Triton
X-100 the anti-K19M antibody (Protein A purified) gave
an intensive granular fluorescence pattern which
appeared perinuclear in a significant fraction of the cells
with a similar pattern observed in H295R and G59/540
cells (Figure 5E,5F). On the other hand, the parent G59
cell line showed a weak, but still perinuclear cytoplasmic
staining (Figure 5G). The latter may represent a smaller
endogenous isoform of CCN3.
Western blot analysis Figure 1
Western blot analysis. Representative gels illustrating the 
expression of CCN3 proteins in H295R, G59/540, and G59 
cell lines. Conditioned medium and cellular lysates were elec-
trophoresed under denaturing conditions and immunoblot-
ted with anti-K19M IgG antibody. A. Starts: 1). supernatant 
collected form H295R cell line; 2). G59/540 transfected cells 
supernatant; 3). supernatant from G59 CCN3 negative cells; 
4). lysate from H295R cells; 5). lysate from G59/540 cells; 6). 
lysate from G59 cells showing two bands at 48 kDa and 30 
kDa.
Reactivity of affinity purified anti-K19M-AF antibodies in  ELISA Figure 2
Reactivity of affinity purified anti-K19M-AF antibodies in 
ELISA. Affinity chromatography fractions were tested in wells 
coated with: a) GST 1 µg/ml (hatched columns); b) GST-
CCN3 1 µg/ml (blank columns); c) K19M peptide 1 µg/ml 
(black columns). Column fractions F1 to F3 contain the flow 
through unbound proteins while fractions F4 to F8 contain 
antibody bound to K19M peptide that eluted with glycine 
buffer pH 2.8.Cell Communication and Signaling 2004, 2:9 http://www.biosignaling.com/content/2/1/9
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In summary, the results produced using an immunologi-
cal approach would suggest multiple conformations of
the C-terminal end which harbors the immunogenic
epitopes. Furthermore, these variations are associated
with cell bound and secreted forms of CCN3. Cytoplasmic
localization indicated abundant CCN3 protein localized
with ER and Golgi networks.
Discussion
In this study we exploited the range of binding affinities
present in polyclonal antibodies raised against the C-ter-
minal peptide of CCN3 and analyzed with different
immunoaffinity methods to ask whether CCN3 exists in
alternate conformational forms in cell cultures and super-
natants. Whereas immunocytochemistry of fixed, perme-
abilized and non-permeabilized cells yielded evidence of
both cell surface membrane and cytoplasmic expression
and topographical distribution of native CCN3, ELISA
method and western immunoblot revealed different pos-
sible conformational forms of CCN3. Taken together the
results of the assays suggest that native CCN3 assumes dif-
ferent configurations that either expose or sequester the C-
terminal peptide depending on whether CCN3 is cell
associated or free within the culture supernatant. When
considered in the light of recent evidence indicating that
CCN3 can associate with specific integrins at the cell
membrane [23,24] the question also arises whether CCN3
associates with specific protein partners in the circulation
and in the extracellular matrix produced by different cell
types.
In these studies we focused on two cell lines, H295R and
G59, representing adrenocortical and glial tissues, signifi-
cantly different in their anatomical location and
microenvironment. Since CCN3 has been demonstrated
in plasma [25] it is conceptually feasible that CCN3 may
be secreted by well organized ectodermal, mesodermal
and endodermal cell types where it is expressed [26-28],
and then is transported through complex extracellular
matrix to enter the circulation. Moreover, as CCN3 has
been shown to be expressed by endothelium [23,29], the
source of the circulating CCN3 may be restricted to
endothelium. Keeping to this scenario, tissue expression
of CCN3 would be restricted to regional cell types and its
arena of activity relegated to the extracellular matrix and
resident cells. Interestingly, we could show in vitro that
CCN3 is sequestered in cell footprints representing a
secreted extracellular matrix. Cell footprints can be depos-
ited by various cell types in different arrangements and
consists of extracellular matrix, including a variety of base-
ment membrane proteins [30-32]. In our studies we noted
a more uniform and punctuate deposition of CCN3 in the
footprints suggesting possible association with regularly
arranged clustered partners (e.g. integrins), yet to be deter-
mined. Localization of CCN3 to footprints is perhaps
expected since it has been shown to mediate adhesion of
endothelial cells [23], in turn triggering intracellular phos-
phorylation signaling events.
Absorption ELISA to check the binding of anti-K19M-AF to  CCN3 in liquid phase Figure 3
Absorption ELISA to check the binding of anti-K19M-AF to 
CCN3 in liquid phase. A fixed dilution of anti-K19M-AF (1/
250 in 1% BSA) was mixed with a) serial dilutions of K19M 
peptide -- --- --- -- b) serial dilutions of H295R supernatant, 
positive for CCN-3 --- --- ---; c). G59 supernatant, negative 
for CCN-3 ---x----x---; d). 1% BSA in PBS pH 7.4 --- --- --- -- 
and applied to wells coated with K19M peptide. Each point 
repsent the average of 4 determinations.
Detection of CCN3 expression on cultured cell lines by cell- ELISA Figure 4
Detection of CCN3 expression on cultured cell lines by cell-
ELISA. Cells from H295R line or glioblastoma G59 cells were 
treated with 1% bovine serum albumin in PBS, pH 7.4 (blank 
columns) or K19M-AF diluted 1/500 in 1%BSA (hatched col-
umns). Treatment of cells: A – G59 non-permeabilized cells; 
B – C59 permeabilized cells; C – H295R non-permeabilized 
cells; D – H295R permeabilized cells. Each point repsent the 
average of 4 determinations.Cell Communication and Signaling 2004, 2:9 http://www.biosignaling.com/content/2/1/9
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This then raises the notion that proximity of CCN3 to cell
surfaces could allow CCN3 to function in possible auto-
crine and paracrine mechanisms. Depending on the asso-
ciating proteins, CCN3 would likely undergo specific
conformational changes with potentially different func-
tional outcomes. A variety of functional states may exist
since CCN3 is expressed in secretable and non-secretable
isoforms and contains motifs that overlap with other pro-
teins and therein, additional binding partners [1,4]. Thus
far the actual molecular function of native CCN3 has not
been determined, although biologically it shows evidence
of being able to regulate mitogenesis and motogenesis [3].
In turn, CCN3, compared to other CCN proteins, may be
differentially regulated by mechanical stress [29]. As a
Indirect immunofluorescence staining with the anti-K19M IgG antibody Figure 5
Indirect immunofluorescence staining with the anti-K19M IgG antibody. A, B The H295R and G540 cell lines, paraformaldehyde 
fixed and non-permeabilized, show a similar granular like surface membrane labeling pattern; C, D, Both in H295R and G540 
cultures, paraformadehyde fixed and non-permeabilized, cell footprints are positively labeled; E, F, The H295R and G540 cell 
lines, formalin/ethanol fixed and permeabilized show a granular cytoplasmic labelling pattern that is perinuclear localized in ER 
and Golgi network; G, The G59/540 parent line, formalin/ethanol fixed and permeabilized, still shows a small amount of a peri-
nuclear granular staining pattern.Cell Communication and Signaling 2004, 2:9 http://www.biosignaling.com/content/2/1/9
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heparan binding protein, CCN3 could associate with a
large group of molecules at the cell membrane and in the
extracellular matrix. Yeast two hybrid studies have
indicated associations with fibulin 1C [16]. Other studies
have shown CCN3 involved in calcium signaling [19,33],
associated with Notch signaling [17], and able to trigger
membrane mediated phosphorylation events [34] Some
of the cellular effects of CCN3 may also be mediated by
different isoforms operating at the level of the nucleus
[35].
The biological significance of different conformations of
CCN3 is not known. However, examples from other
studies have suggested that conformational changes can
occur in serum proteins due to binding of bivalent cations
[36]. Since we recently reported that CCN3 may interact
with Ca2+ binding proteins like fibulin-1C, modulate
calcium uptake, and considering that Ca2+ binding mod-
ulates function of other protein partners such as integrins
[reviewed in [33]], it is conceivable that secreted CCN3
could assume an altered conformation by binding biva-
lent cations, directly or indirectly, like Ca2+ present in cul-
ture media. Whether calcium or some other bivalent
cation could be involved and how this could occur is still
speculative as the sequence of CCN3 does not suggest any
obvious cation binding properties. It is also possible that
secreted CCN3 complexes with an as yet unknown partner
thus sequestering the antigenic epitopes.
Altered expression of CCN3 in a variety of cancers may
reflect maintenance of a normal homeostatic function of
the cell of origin, or may indicate requirement of specific
CCN proteins for maintaining the undifferentiated tumor
state. One such example where the two possibilities are
not yet resolved is in Wilms tumor, where CCN3 is abun-
dantly expressed during normal nephrogenesis and in
tumors [12]. Interestingly, CCN3 was originally identified
during MAV virus induction of nephroblastoma but is not
a direct target of WT1, the Wilms tumor suppressor gene
[34]. Thus far few mutations have been described for CCN
family and none for CCN3. CCN proteins have however
been associated with a variety of cancers where they can be
markedly overexpressed [11,37-39]. It may be that CCN
proteins are not directly involved in tumorigenesis (e.g.,
Wilms tumor) but rather play supporting roles or may act
as a negative regulator on malignant behavior reflecting
their roles as integrators of cell-cell and cell-matrix com-
munications. Thus having antibodies that can recognize
the different isoforms of CCN proteins with great specifi-
city and in respect to specific epitopes within the domains
would be invaluable for quantitation [40] and for dissect-
ing their functions in communication signaling.
Conclusions
Our preliminary investigations here have revealed possi-
ble physical and functional states of native CCN3
localizing to cytoplasmic, cell membrane and extracellu-
lar matrix. Further complexity is added since shorter and
larger isoforms of CCN3 can be detected using western
blotting. The origin of these short forms is still not fully
understood. As there do not appear to be alternate tran-
scripts [1] this suggests post-translational processing
including, in addition to variant glycosylation, phosphor-
ylation, specific proteolytic events and sites. The C-termi-
nal antibody recognizes these forms. The use of
antibodies to other motifs in CCN3 will permit us to track
the cleaved N-terminal peptide which potentially could
be functionally active as it resembles IGFBP [1]. Therefore
the cleavage products of CCN3 in concert with native
CCN3 may also be involved in several aspects of the regu-
lation of growth factor activity at the cell membrane or its
management in extracellular repositories.
Finally, cells can coordinately express a variety of CCN
proteins that are closely related, for example CCN1-3 with
cross-over and opposite functional effects yet bearing
similar functional domains. Evidence is starting to surface
that they might compete for binding partners, such as
integrins, thus forming protein complexes with different
biological consequences to cell behavior [18,19]. It will be
important to understand how stoichiometric changes in
CCN protein concentrations can change the behavior of
cells, thus opening up opportunities for therapeutic
manipulations in disease. It is obvious that there will be a
necessity for antibody reagents and quantitative method-
ologies to enable these studies.
Materials and methods
Cell Lines
NCI H259R (American Type Cell Collection) is a human
adenocortical carcinoma cell line and was cultured in
DMEM/F12 supplemented with 2.5 % Nu-serum plus
ITS+ supplement (Sigma Co, St. Louis, USA). H295R cells
have been characterized and were shown to secrete high
levels of CCN3 protein [20,21]. The glioblastoma cell line
(G-59) has been described previously [22]. CCN3 express-
ing G59/540 sublines were obtained following transfec-
tion of G59 with pCMV CCN3 plasmid and G418
selection [13]. These cell lines and their derivatives were
used in cell ELISA and indirect immunofluorescence labe-
ling experiments as described below.
Antibodies
Antibodies against C-terminal peptide K19M were used in
these experiments after either purification by an antigen
specific affinity chromatography (anti-K19M-AF) or by
Protein A chromatography (anti-K19M IgGs).Cell Communication and Signaling 2004, 2:9 http://www.biosignaling.com/content/2/1/9
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Antibody Affinity Purification and Characterization
The K19M C-terminal peptide (KNNEAFLQELELKT-
TRGKM) of human CCN3 protein was coupled to CNBr
activated Sepharose 4B (Pharmacia Biotech, Uppsala,
Sweden) following the protocol recommended by the
manufacturer. Briefly, 3 mg of peptide were dissolved in 5
ml of 0.1 M NaCO3 pH 9.0 containing 0.5 M NaCl (cou-
pling buffer) and added to 3.5 ml CNBr-Sepharose
swelled gel and the mixture was rotated end-over-end for
2 hours at room temperature. Excess ligand was eluted
with 20 ml of coupling buffer and the gel was incubated
in 0.1 M Tris-HCl buffer pH 8.0 for 2 hours at room tem-
perature. The gel was washed 5 times in cycles consisting
of 20 ml of 0.1 M acetate buffer pH 4.0 followed by 20 ml
of 0.1 M Tris-HCl buffer pH 8.0, each containing 0.5 M
NaCl, and then packed into a PD-10 column.
The rabbit anti-K19M antiserum was absorbed with 1 mg/
ml human serum albumin to remove cross-reactivity with
human plasma and dialyzed overnight at 4°C against
phosphate buffer pH 7.0. An aliquot of 3.5 ml serum was
loaded on the affinity column and the flow through and
the unbound proteins were collected in 3 ml fractions fol-
lowed by thorough washing of the column with the load-
ing buffer. The K19M peptide bound antibodies were
eluted with 9 ml of 0.1 M Tris-glycine buffer pH 2.8 in 3
ml fractions that were collected into test tubes containing
100 µl 1 M Tris buffer pH 8.0. All column fractions were
tested by ELISA for the presence of antibodies reacting
against K19M peptide and the positively reacting fractions
were further purified by affinity chromatography on pre-
packed HiTrap Protein A columns (Pharmacia Biotech,
Uppsala, Sweden) as recommended. Affinity purified
antibody preparations were further tested to determine
their reactivities and specificities. The affinity purified
anti-K19M-AF antibodies reacted against the K19M pep-
tide when tested in serial dilutions in ELISA (see below).
The titers of K19M-AF antibodies were comparatively
lower as compared to the unfractionated K19M antise-
rum. This finding was not unexpected as it likely reflects
the polyclonal composition of the primary rabbit antise-
rum and differences in the content of the specific mono-
clonal specificities in the antiserum. Importantly, the
affinity purified antibodies recognized the K19M peptide
when coated on a solid phase.
K19M Peptide Enzyme-linked Immunoabsorbent Assay 
(ELISA)
Affinity purified antibodies were titered by ELISA. Individ-
ual wells of polystyrene 96-well flat bottom plates
(NUNC) were coated with 1 µg/ml of K19M peptide
diluted in coating buffer (0.05 M carbonate buffer pH 9.6)
by incubation overnight at 4°C. The unsaturated protein
binding sites were blocked with 300 µl/well 2% BSA for 1
h at room temperature. The primary anti-K19M antiserum
and affinity purified antibodies were added in serial dilu-
tions in duplicates and the wells were incubated for 2 h at
room temperature. After thorough washing the wells were
incubated with goat anti-rabbit IgG serum conjugated
with peroxidase (Sigma Co) diluted 1/5000 in blocking
buffer for 1 h at room temperature. The bound enzyme
activity was revealed by adding the enzyme substrate 0.5
mg/ml ortho-phenylenediamine in citrate buffer pH 5.0
containing 0.5 µl/ml H202. The enzyme reaction was
stopped by addition of 50 µl/well of H2SO4 and the color
reaction was read at 492 nm in a MicroELISA reader.
Cell Enzyme-Linked Immunoabsorbent Assay (Cell ELISA)
Tumor cell lines were cultured in complete medium in 96-
well flat bottom plates (Corning) to form a subconfluent
monolayer and further incubated overnight in serum free
medium. The cells were washed 3 times for 5 min each
with phosphate buffered saline (PBS, pH 7.2) and cells
were fixed by treatment with ice-cold methanol for 30
min warming to room temperature. The endogenous per-
oxidase activity was blocked with 3% H2O2 in distilled
water for 7 min at room temperature followed by 3 × 5
min washes in PBS, pH 7.2. Non-specific binding was
blocked with 1% bovine serum albumin (BSA) for 1 h at
room temperature. Cells were washed once in PBS and
incubated with K19M-AF diluted in 1%BSA for 2 h at
room temperature. After 3 × 10 min washes in PBS goat-
anti rabbit IgG conjugated with peroxidase diluted 1/
10000 in 1% BSA-PBS was added for 1 hour at room tem-
perature. The cells were washed again in PBS and the
bound enzyme activity was developed by adding ortho-
phenylendiamine (5 mg/10 ml citrate buffer, pH 5.0)
containing 5 µl of 30% H2O2. The color reaction was
stopped by adding 50 µl of 10% H2SO4 and the intensity
was read at 492 nm in a MicroELISA reader.
Gel Electrophoresis and Western blotting
To prepare proteins for immunoblotting, cells were lysed
in NP40 buffer (50 mM Tris hydrochloride, pH 8.0, 150
mM NaCl, 5 mM EDTA and 2% NP40) with protease
inhibitors (Cocktail Tablets, complete, Roche) and phos-
phatase inhibitors (50 mM NaF, 2 mM sodium
orthovanadate) for 30 min at 4°C. After centrifugation at
15 000 g, extracts were stored at -80°C until use. CCN3
proteins in the conditioned medium were concentrated
on Heparin Sepharose (Amersham, Uppsala, Sweden) as
described by Chevalier et al (1998). Briefly, supernatants
were incubated overnight with heparine and then washed
4 times in PBS containing protease inhibitors. Bound
CCN3 was dissociated using 2-mercaptoethanol in Lae-
mmli buffer, boiled for 10 min and then centrifuged to
keep the free protein. Heparin Sepharose concentrated
samples and cellular extracts were subjected to electro-
phoresis under reducing conditions in 12.5% polyacryla-
mide gels. Separated proteins were subsequentlyCell Communication and Signaling 2004, 2:9 http://www.biosignaling.com/content/2/1/9
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transferred to nitrocellulose by a semi-dry blotter (LKB
Biotech, Sweden) as recommended by the supplier. The
nitrocellulose sheet was blocked by incubation for 1 hour
at room temperature with 5% nonfat milk in PBST (PBS
with 0.2% Tween 20, pH 7.4). The membrane was then
incubated in the same buffer with the anti-K19M IgG (1/
2000) and then washed extensively. The blots were further
incubated in goat anti-rabbit IgG conjugated with peroxi-
dase (1/10 000 in blocking solution, Sigma Co, USA) for
1 hour at room temperature. Revelation was performed
using the chemoluminescence protocol and reagents
(Pierce, Rockford, IL, USA).
Indirect Immunofluorescence Labeling
Cells were grown on alcohol flamed coverslips, rinsed in
PBS and fixed in cold 70% ethanol containing 10% for-
malin (Sigma) for 10 min on ice, and stored in PBS.
Immunofluorescence labeling was performed at room
temperature. For this procedure, coverslips were placed
into weighing boats [Sigma; 4.5cm × 4.5cm] maintaining
cell side up. Cells were further permeabilized in 0.5% Tri-
ton X-100 in PBS for 15 min and then blocked in 5%FBS/
PBS for 30 min.
Anti-K19M IgGs antibodies were applied at 1:1000 dilu-
tion in 5%FBS/PBS for 1 hour with intermittent rotation,
followed by 5 washes in PBS containing 0.1% Tween 20.
Subsequently, the cells were incubated in anti-rabbit IgG
serum conjugated with either Alexa 488 (green fluores-
cence) or Alexa 594 (red fluorescence), in 5%PBS/BSA for
1 hour. After final washes in PBS/Tween 20 followed by
one wash in PBS cells were mounted with antifade mount-
ing medium (Bio-Rad, France), excess liquid adsorbed
with filter paper, and coverslips sealed with clear nail
polish. Immunofluorescence images were captured on
400 ASA film and processed further with Adobe Pho-
toshop (version 7.0).
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